Letter: association between proton pump inhibitor use and fracture risk ‐ causality or confounding?

of autoimmune hepatitis in the real world. Aliment Pharmacol Ther. 2017;45:723-732. 3. Mousa HS, Carbone M, Malinverno F, et al. Novel therapeutics for primary biliary cholangitis: toward a disease-stage-based approach. Autoimmun Rev. 2016;15:870-876. 4. Molinaro A, Marschall HU. Why doesn’t primary biliary cholangitis respond to immunosuppressive medications? Curr Hepatol Rep. 2017;16:119-123. 5. Aqel BA, Machicao V, Rosser B, et al. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol. 2004;38:805-809. 6. Tannous MM, Cheng J, Muniyappa K, et al. Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience. Aliment Pharmacol Ther. 2011;34:405-407. 7. Than NN, Wiegard C, Weiler-Normann C, et al. Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy. Scand J Gastroenterol. 2016;51:329-336. 8. Efe C, Hagstrom H, Ytting H, et al. Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis. Clin Gastroenterol Hepatol. 2017;15: 1950-1956. e1

[1]  Jiamei Wang,et al.  Letter: proton pump inhibitor use and risk of fracture , 2018, Alimentary pharmacology & therapeutics.

[2]  E. Larson,et al.  Proton pump inhibitor use and the risk of fractures among an older adult cohort , 2018, Pharmacoepidemiology and drug safety.

[3]  N. van der Velde,et al.  Fall-Risk-Increasing Drugs: A Systematic Review and Meta-analysis: III. Others. , 2018, Journal of the American Medical Directors Association.

[4]  A. Tanskanen,et al.  Proton pump inhibitor use and risk of hip fractures among community‐dwelling persons with Alzheimer's disease—a nested case‐control study , 2018, Alimentary pharmacology & therapeutics.

[5]  T. Sugiyama.  Letter: proton pump inhibitor use and fracture risk , 2018, Alimentary pharmacology & therapeutics.

[6]  L. Targownik.  Editorial: Non‐breaking news! High‐dose PPIs likely do not cause fractures , 2018, Alimentary pharmacology & therapeutics.

[7]  C. Schleck,et al.  Incidence and predictors of osteoporotic fractures in patients with Barrett's oesophagus: a population‐based nested case‐control study , 2017, Alimentary pharmacology & therapeutics.

[8]  Hongfang Liu,et al.  Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System , 2017, Scientific Reports.

[9]  W. Winkelmayer,et al.  Proton Pump Inhibitor Use and Risk of Hip Fracture in Kidney Transplant Recipients. , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  D. Melzer,et al.  Proton-Pump Inhibitors and Fragility Fractures in Vulnerable Older Patients , 2017, The American Journal of Gastroenterology.

[11]  C. Liang,et al.  Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study , 2017, Osteoporosis International.